Scientists at Northwestern University have developed a promising injectable therapy that could help reduce brain damage following an ischemic stroke. The treatment uses specially designed molecules delivered through a standard intravenous (IV) injection after blood flow is restored. Although reopening a blocked artery is essential, the return of circulation can trigger inflammation and additional tissue damage, known as reperfusion injury. Researchers hope this new approach could eventually help protect vulnerable brain cells and improve recovery.
The experimental therapy uses supramolecular therapeutic peptides, nicknamed “dancing molecules,” developed by Northwestern professor Samuel I. Stupp and his team. These tiny structures are designed to interact with cellular receptors and deliver signals that may support tissue repair. In earlier research, related technology showed potential for promoting recovery after spinal cord injuries in mice. For stroke treatment, scientists modified the approach so the molecules could travel through the bloodstream and reach injured brain tissue.
In a preclinical study published in Neurotherapeutics, researchers tested the therapy in mice after temporarily blocking blood flow to the brain and then restoring circulation. Animals receiving the injection showed less brain tissue damage and reduced signs of inflammation compared with control animals. Researchers also found that the molecules accumulated around the injured brain region, suggesting they could take advantage of temporary changes in the blood-brain barrier after a stroke. Initial safety assessments found no significant organ toxicity, although further testing is needed.
Despite these encouraging findings, the treatment remains experimental and has not been proven effective in humans. Behavioral tests in the study did not show significant differences between treated and untreated mice, highlighting the need for further research into functional recovery and long-term benefits. Scientists must conduct additional studies before human clinical trials can establish whether the therapy is safe and effective. If future research succeeds, the IV treatment could potentially complement existing stroke care by helping limit secondary damage and encouraging the brain’s natural repair processes. 💙
